|LETTER TO THE EDITOR
|Year : 2020 | Volume
| Issue : 6 | Page : 1016-1018
Routine testing not beneficial in evaluation of patients with chronic spontaneous urticaria
Sujoy Khan, Rebecca Avison
Department of Immunology and Allergy, Hull University Teaching Hospitals NHS Trust, Queen's Center, Castle Hill Hospital, Cottingham, United Kingdom
|Date of Submission||27-Mar-2020|
|Date of Decision||07-Apr-2020|
|Date of Acceptance||01-Jun-2020|
|Date of Web Publication||19-Sep-2020|
Department of Immunology and Allergy, Hull University Teaching Hospitals NHS Trust, Castle Hill Hospital, Castle Road, Cottingham, HU16 5JQ
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Khan S, Avison R. Routine testing not beneficial in evaluation of patients with chronic spontaneous urticaria. Indian Dermatol Online J 2020;11:1016-8
|How to cite this URL:|
Khan S, Avison R. Routine testing not beneficial in evaluation of patients with chronic spontaneous urticaria. Indian Dermatol Online J [serial online] 2020 [cited 2021 Jan 27];11:1016-8. Available from: https://www.idoj.in/text.asp?2020/11/6/1016/295423
We read with interest the paper by Shailaja Chauhan and colleagues where they found that elevated plasma levels of D-dimer in patients with chronic spontaneous urticaria (CSU) may influence treatment options, but the tests did not make any difference in the overall management of patients. We present our experience with a quality improvement project, which determined the usefulness of routine testing in CSU. The British Society of Allergy & Clinical Immunology guidelines were used as standards [Table 1] and was approved by the Clinical Audit and Effectiveness Team of Hull University Teaching Hospitals NHS Trust. Patients with CSU were identified from clinic letters. The first phase (Plan, Do, Study Act Cycle 1) reviewed 169 new consultations for 7 months between September 2018 and March 2019, with a follow-up phase (PDSA Cycle 2) of 190 new consultations for 4 months between September 2019 and December 2019. Performances with regards to standards are shown in [Table 1].
|Table 1: Standards used for the quality improvement project with results|
Click here to view
A total of 763 blood tests were done on 44 patients (34 females; mean age 42.6 years with age range 17-83 years) in the first phase of the project. Of these, 12 were abnormal but only 2 (0.3%) results led to a change in the management (IgG lambda paraprotein, thyroiditis with undetectable thyroid-stimulating hormone (TSH)) [Figure 1]. 93 specific IgE tests were done and 14 patients underwent further skin tests of which 71% of skin tests were either dermographic or negative. The positive specific IgE tests were to aero-allergens such as house dust mite or animal dander that were identified on skin tests but patients felt that this was not new information, or changed the way CSU was managed. In total, 84% of patients had 25-hydroxy-vitamin D3 levels tested, and 87% of patients had vitamin B12, folate and ferritin levels tested. The total cost of evaluating patients with urticaria (excluding complement C3, C4, and C1-inhibitor tests) was at least $2400 (equivalent to INR 1,80,000). Based on the findings of PDSA Cycle 1, the Directory of Services (DoS) for Immunology was revised and a pathway for referral into secondary care was published. The investigations that could be requested at CSU evaluation were changed to include: full blood count, biochemistry profile, thyroid function (TSH, fT4 if on thyroid medication), tryptase with complement C3 and C4 testing reserved only for patients with angioedema.
|Figure 1: Routine tests in patients with chronic spontaneous urticaria have limited utility. The first phase showed only 2 (0.3%) of 763 tests made a change in overall management indicating an excess of tests were being requested. While there was an improvement in the numbers of tests requested in the second phase, still only 1 (0.4%) of 262 tests influenced clinical management|
Click here to view
The second phase (PDSA Cycle 2) identified 30 patients (22 females; mean age 40.9 years with range 16-92 years) with chronic spontaneous urticaria and angioedema where a total of 262 tests were done (including 73 specific IgE tests). Of these, 21 results were abnormal and only one (0.4%) altered management (positive specific IgE to ω-5-gliadin) [Figure 1]. No skin prick testing, 25-hydroxy-VitaminD3 levels or hematinics (folate, ferritin, vitamin B12) were requested in this cycle. The positive specific IgE results were against aero-allergens (dust mites, animal dander, pollens) similar to what was identified in the first phase, and did not influence management other than helping patients realize management of underlying atopy/environmental allergies will help control the urticaria. The total cost of evaluating patients in the second phase was at least $800 (equivalent to INR 60,000), accounting for tests done in the majority of patients. There was an improvement in 28% points that met the standards.
In conclusion, there was no evidence that routine testing in the evaluation of CSU made any change in treatment or that patient safety is likely to be compromised if no tests were offered, if the clinical history was accurate. Although the DoS allowed minimum tests that could be offered, it had a less than expected effect on the way testing was recommended. Our findings are consistent with that of Carrillo-Martin I et al. where only 0.9% of patients (5 of 725 patients) had a change in outcome with routine testing and $569 were spent in evaluation, management, and costs of tests. However, we agree that it is completely acceptable to request blood tests as per clinical need such as an antinuclear antibody (when the urticaria presents with features of connective tissue disease such as joint pains, photosensitive skin rash, etc), C-reactive protein or serum electrophoresis or skin biopsy (features of autoinflammation such as Schnitzler syndrome), thyroid autoantibodies (if there is a strong family history of autoimmune thyroid disease), including special tests where specific centers have the facility to perform an autologous serum skin test or the basophil CD63/CD203c expression tests.,,
We feel that the reasons for testing patients are probably influenced by multiple factors such as (1) pressure on physicians to ensure that there are no secondary triggers; (2) negative allergy results may decrease anxiety; (3) conflicting opinions of physicians about ‘triggers'; and (4) tendency to generalize reports that have identified some biomarkers in certain types of CSU. We hope this additional data will be of value in convincing caregivers that routine testing in patients with CSU is of low benefit and only adds to the ongoing costs of therapy.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Chauhan S, Mahajan VK, Mehta KS, Yadav RS, Chauhan PS, Bhushan S, et al
. Clinicoepidemiologic features of chronic spontaneous urticaria in patients with elevated plasma D-dimer levels versus those without it: A case-control cross-sectional study of 100 Indian patients. Indian Dermatol Online J 2019;10:632-8. [Full text]
Powell RJ, Leech SC, Till S, Huber PA, Nasser SM, Clark AT; British Society for Allergy and Clinical Immunology. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy 2015;45:547-65.
Carrillo-Martin I, Dudgeon MG, Chamorro-Pareja N, Haehn DA, Rivera-Valenzuela MG, Spaulding AC, et al
. Cost-utility of routine testing in chronic urticaria/angioedema: A cohort study. J Allergy Clin Immunol Pract 2019;7:2823-32.
Gonzalez-Diaz SN, Sanchez-Borges M, Rangel-Gonzalez DM, Guzman-Avilan RI, Canseco-Villarreal JI, Arias-Cruz A. Chronic urticaria and thyroid pathology. World Allergy Organ J 2020;13:100101.
Chen Q, Zhai Z, Xu J, Chen W, Chen S, Zhong H, et al
. Basophil CD63 expression in chronic spontaneous urticaria: Correlation with allergic sensitization, serum autoreactivity and basophil reactivity. J Eur Acad Dermatol Venereol 2017;31:463-8.
Gusdorf L, Lipsker D. Neutrophilic urticarial dermatosis: An entity bridging monogenic and polygenic autoinflammatory disorders, and beyond. J Eur Acad Dermatol Venereol 2020;34:685-90.